Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.
about
Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, TexasCefditoren in upper and lower community-acquired respiratory tract infectionsEvolution and global dissemination of macrolide-resistant group A streptococci.Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial.Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistanceBlood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapyOptimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003Community prescribing and resistant Streptococcus pneumoniae.Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique.Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Asia-Pacific consensus guidelines on gastric cancer prevention.Population biology of the human restricted pathogen, Streptococcus pyogenes.Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.Systemic antibiotic use among children and adolescents in Germany: a population-based study.Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001.Patterns of macrolide resistance determinants among S. pyogenes and S. pneumoniae isolates in Saudi Arabia.
P2860
Q33836641-03F70E5A-B655-4D7A-BC6A-CDD4E26B4EE5Q34574090-67438F76-019F-43B1-846C-6BFEF589E5FAQ35023314-AB111FCC-2D1C-421D-8D4D-EEDF6EE45C7AQ35026577-675BE9D3-7DC1-46E2-A49D-A4312AE03B03Q35622545-00690628-10F9-464D-A1B2-6CBF0039883EQ35689377-2E84AF51-0AED-4609-94DF-BCDAB0D4614AQ35692693-FB47E471-0EB6-4008-80A2-E360D3354B43Q36009330-86534CA8-1954-42E2-BA83-36170B2BA0B0Q36009361-924A1DAF-25B0-49A5-BC82-26A36AAFB1F7Q36243482-BB8C3E23-AA5A-4931-BD52-DC6E9E42675FQ36723792-21920437-21DD-4898-B5DA-1AB90907309EQ36744739-10096C98-969C-4B4C-99ED-6269342C0905Q37101686-AA9D364E-0274-4ECE-ACAC-8F45407BD3AFQ37201383-7AE3A127-5D35-4253-A8DA-10891AFAD126Q37420239-8C4857CF-4E48-41B8-B781-F61FF5E298EBQ40257972-F2F02CF6-E707-4AF1-828D-B258DE38936CQ44883929-74C0E214-C1F6-4572-B1D4-361E4774FD5FQ46530101-949FB493-5719-4BD2-BE43-B64D34329F6F
P2860
Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@ast
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@en
type
label
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@ast
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@en
prefLabel
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@ast
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@en
P2093
P2860
P1476
Pharmacoepidemiological analys ...... us pyogenes isolates in Spain.
@en
P2093
P2860
P304
P356
10.1128/JCM.40.8.2959-2963.2002
P407
P577
2002-08-01T00:00:00Z